Drug bidding meets the trend of "active" price reduction of enterprises, with a maximum decline of nearly 80%

Source: China Economic Net 2017-09-07 [Huicong pharmaceutical industry net] recently, national pharmaceutical The comprehensive management information platform for supply assurance issued the notice of Yunnan Province on enterprise application for price reduction The prices of 5ml (including 25mg of gingko diterpenoid lactone) gingko diterpenoid lactone meglumine injection produced by Jiangsu Kangyuan Pharmaceutical Co., Ltd and pemetrexed disodium for injection produced by Nanjing Pharmaceutical Factory were reduced respectively According to statistics by the Securities Daily, pharmaceutical manufacturers including Bayer and Roche have made "active" price cuts on their products this year, with a maximum drop of 78.3% "The pharmaceutical environment has changed significantly since this year." In an interview with reporters, Shi lichen, founder of the third-party medical service platform, McConnell, said that the continuous control of medical insurance fees, reducing the proportion of drugs and cracking down on commercial bribery had forced enterprises to readjust their thinking "The bidding price reduction is the general trend" According to the information released by Yunnan provincial government procurement and transfer center, the price of the above-mentioned ginkgo diterpenoid lactone glucosamine injection produced by Kangyuan Pharmaceutical Co., Ltd will be reduced from 612.85 yuan / injection to 316 yuan / injection, with a decrease of about 48%; the price of pemetrexed disodium for injection produced by Nanjing Pharmaceutical factory will be reduced from 3800 yuan / bottle to 2100 yuan / bottle, with a decrease of 44.7% Among them, gingko diterpenoid lactone and meglumine injection is one of the 36 negotiating varieties that have successfully entered the national medical insurance catalogue this year On August 31, Shanghai Medical centralized bidding and purchasing Affairs Management Office released that the rivaroxaban tablets produced by Bayer medical and health care Co., Ltd dropped from 364.35 yuan per box to 138 yuan, a decrease of 62% In addition, the procurement platform of Liaoning Province issued five notices on price reduction of drugs, including two drugs of Jinzhou AoHong Pharmaceutical Co., Ltd and three drugs of Bayer medical and health care Co., Ltd Zhejiang Province has released information on adjusting the linkage (purchase) price adjustment of products such as somatostatin for injection, omeprazole sodium for injection, olacetam injection, candesartan ester tablets, etc Anhui Province issued the announcement that Shanghai Roche Pharmaceutical Co., Ltd applied to reduce the price of "pegylated interferon a-2a injection" produced by the enterprise in the province It is worth mentioning that Yunnan has issued a notice on the price adjustment of Danshen injection The price of Danshen injection produced by Shenwei pharmaceutical dropped from 9.95 yuan / piece to 2.15 yuan / piece, a decrease of 78.3% In addition to drugs, there are also enterprises in the field of medical devices that take the initiative to reduce prices For example, the price of implantable ECG event detector produced by Medtronic (Shanghai) Management Co., Ltd will rise from 47500 yuan to 38990 yuan Compared with the above-mentioned drugs, the decline of drugs produced by some multinational pharmaceutical companies is not large According to the information released by Yunnan Province, the price of imatinib mesylate tablets produced by Novartis Pharmaceutical Co., Ltd dropped from 11890 yuan / box to 10800 yuan / box, a drop of only 9% The price of nilotinib capsule (specification 0.2g) decreased from 36600 yuan / box to 35036.04 yuan / box, with a decrease of about 4% The price of nilotinib capsule (specification 0.15g) decreased from 29365.42 yuan / box to 29000 yuan / box, with a decrease of about 1.2% According to the information inquired by the State Food and drug administration, nilotinib capsule is an imported drug, and Novartis is the only manufacturer of the drug in China In addition to Novartis, imatinib mesylate tablets are also produced by Ouyi Pharmaceutical Co., Ltd of Petrochemicals Group and Haosen Pharmaceutical Co., Ltd of Jiangsu Province According to the research report issued by Tianfeng securities, as far as the bidding results have been completed, the price reduction range of rigid drugs and representative varieties is relatively low; the price reduction pressure of generic drugs and competitive varieties is large; the price reduction range of partial auxiliary drugs is large; the decline range of key imported varieties is limited, and the price difference between the original research drugs and the first imitation of national products has not been reduced Price reduction has become the general trend "The trend of medical insurance fee control bidding price reduction is clear, the whole pharmaceutical industry will continue to bear pressure in a certain period of time." Tianfeng Securities believes "The government requires medical institutions to reduce the proportion of drugs If enterprises want to enter the hospital, they must reduce prices." Mr Shi told reporters that, especially now that the government is cracking down on commercial bribery, enterprises have to take measures to keep the market In addition, fierce market competition, patent expiration and other factors are also one of the factors for drug price reduction For example, according to information released by the State Food and drug administration, pemetrexed disodium for injection has as many as 28 batches In the view of insiders, price reduction is the general trend In 2016, the first batch of national medical insurance catalog negotiation varieties were only 3 In 2017, 36 products entered the national medical insurance catalog, most of which are products of multinational pharmaceutical companies Pharmaceutical companies borrow price cuts in exchange for sales Kangyuan pharmaceutical once said that the price reduction of gingko diterpenoid lactone and meglumine injection had a certain impact on the gross profit margin of the product, but it would greatly reduce the burden of medical expenses of patients and play a positive role in promoting the scale of sales of the drug It is worth mentioning that the price reduction has been extended from Medicare drugs to non Medicare products, that is, self paid drugs According to the reporter, in order to control the proportion of drugs, some regions have already opened their own medicine On May 26, 2017, the implementation opinions on Further Strengthening the construction of business style and rectifying drug kickbacks released by the website of Shanghai Health and Family Planning Commission clearly stated that "strengthen the management of self paid drugs and reasonably control the self paid medical expenses"; "gradually reduce the proportion of self paid drugs and incorporate the proportion of self paid drugs into the hospital performance appraisal"; the self paid drugs used by medical institutions must be discussed The purchase price shall not be higher than the purchase price of the same type of enterprise in Beijing, Tianjin and other places In addition, Chongqing drug exchange also released the notice on joint price negotiation of non-medical insurance drugs in Chongqing public hospitals.